Navigation Links
BiPar Begins Phase 2 Study of Lead PARP Inhibitor in Triple-Negative Breast Cancer Based on Overexpression Biomarker Data
Date:11/15/2007

with the PARP inhibitor BSI-201," said Joyce O'Shaughnessy, M.D., lead investigator, Texas Oncology, PA, Baylor-Sammons Cancer Center in Dallas, US Oncology, and co-chair of the breast cancer research committee of the US Oncology Research Network. "There is a compelling need for a novel approach to treating this high-risk population."

The Phase 2 trial of BSI-201 in patients with triple-negative breast cancer will enroll 120 women in a multicenter, randomized, open-label trial that will compare standard chemotherapy with or without the addition of BSI- 201.

The research presented in Brussels showed the results of an analysis of PARP gene expression in 169 infiltrating ductal breast cancers through the use of the Gene Logic Inc. (Nasdaq: GLGC) BioExpress(R) System database. PARP expression was above the 99.9 percent upper confidence limit for normal tissue in 45 percent of all breast tumors, compared with 75 percent of breast tumors that were estrogen-negative and progesterone-negative and 90 percent of HER2- negative patients.

PARP is a well-characterized and validated target for cancer therapies. PARP plays a central role in cell proliferation in DNA repair, and the PARP-1 gene is upregulated in certain tumor types.

BiPar's novel, proprietary PARP inhibitors are a new generation of drug candidates that show promising activity and a favorable toxicity profile. Preclinical and early clinical studies suggest the drugs selectively induce tumor cell death and are active against a broad range of tumor types. In addition to the trial in patients with triple-negative breast cancer, BiPar plans to begin a series Phase1b and Phase 2 trials of BSI-201 in other major cancers that overexpress PARP over the next
'/>"/>

SOURCE BiPar Sciences, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. BiPar Expands Management Team to Advance Lead PARP Inhibitor Product Candidate Into Phase 2 Trials for Cancer
2. BiPar Announces Preclinical Data Demonstrating Anti-Tumor Activity With BSI-401, Its Second-Generation PARP Inhibitor
3. BiPar Genomic Biomarker Data Demonstrate Overexpression of PARP-1 Gene in Multiple Cancer Types
4. Par Pharmaceutical Begins Shipment of Additional Dosage Strength of Generic TOPROL-XL(R)
5. MacroGenics Begins Global Phase 2/3 Protege Study in Recent-onset Type 1 Diabetes Mellitus
6. Enrollment Begins on Human PK Study for Medidur(TM) FA
7. Vical Begins Phase 1 Trial of DNA Vaccine Against H5N1 Pandemic Influenza
8. Sucampo Pharmaceuticals, Inc. Begins Pivotal Phase III Studies of Oral Lubiprostone to Treat Opioid-Induced Bowel Dysfunction (OBD)
9. Rockwell Medical Technologies, Inc. Begins Patient Enrollment for its SFP Dose-Ranging Study
10. Metabolex Begins Phase 2 Trial of MBX-8025 for Treatment of Dyslipidemia
11. DiObex Begins Dosing Patients in Phase 2b Trial of Type 2 Diabetes Drug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/12/2014)... , September 12, 2014 ... Market by Application [Beverages (Alcoholic, CSD, Sports & Energy ... Pet Food, Meat & Seafood)], by Material (Aluminum ... by MarketsandMarkets, defines and segments the Food & ... of each application in terms of volumes and ...
(Date:9/12/2014)... , Sept. 12, 2014 /PRNewswire-iReach/ -- 9 th ... 22-24, 2014 – Bethesda, MD ... http://www.fdanews.com/9thInspectionsSummitEarlyBird   Photo - http://photos.prnewswire.com/prnh/20140912/145652 ... for the next inspection than to get a glimpse ... during and after an inspection. Come to ...
(Date:9/12/2014)... 12, 2014 Research and Markets ... "Global Medical Technologies Market 2014-2018" report to ... a collective term for software solutions, medical devices, ... health. The Global Medical Technologies market covers active ... In vitro diagnostics technology, dental technology, electromechanical medical ...
Breaking Medicine Technology:Food & Beverage Metal Cans Market Worth $49.20 Billion by 2019 2Food & Beverage Metal Cans Market Worth $49.20 Billion by 2019 3Food & Beverage Metal Cans Market Worth $49.20 Billion by 2019 4FDAnews Announces: Early Bird Registration Discount Ends Sept.19 for 9th Annual Inspections Summit, Oct. 22-24, 2014 2FDAnews Announces: Early Bird Registration Discount Ends Sept.19 for 9th Annual Inspections Summit, Oct. 22-24, 2014 3Global Medical Technologies Market 2014-2018: Key Vendors are GE, Johnson & Johnson, Medtronic, Roche and Siemens 2Global Medical Technologies Market 2014-2018: Key Vendors are GE, Johnson & Johnson, Medtronic, Roche and Siemens 3
... and CAMPBELL, Calif. , May ... sophisticated risk characterization and personalized therapy guidelines for ... of advanced tests, offering an accompanying nutrition program, ... Director stated:  "With appropriate risk characterization and treatment, ...
... May 25 The U.S. Food and Drug Administration approved Lumizyme (alglucosidase ... a rare genetic disorder. , , ... http://www.newscom.com/cgi-bin/prnh/20090824/FDALOGO ) , , , ... an estimated 1 in every 40,000 to 300,000 births. Its primary symptom is ...
Cached Medicine Technology:Health Network Laboratories (HNL) Enters Into License Agreement With Hunter Laboratories to Provide HunterHeart Cardiovascular Disease Management Program. 2FDA Approves New Treatment for Late-Onset Pompe Disease 2FDA Approves New Treatment for Late-Onset Pompe Disease 3
(Date:9/15/2014)... (PRWEB) September 15, 2014 These events ... business requirements are in each state; and how to ... include industry professionals, such as medical marijuana pioneer ... and cannabis business consultant Travis Howard of Shift ... running legal marijuana businesses all over the United States. ...
(Date:9/15/2014)... 15, 2014 Concox , a ... wireless communications equipment, is dedicated to bringing reliable products ... Being the best-seller in Concox’s products, GT06N not only ... customers. GT06N is a mini and original GPS car ... be installed in the shelters on cars or trucks. ...
(Date:9/14/2014)... 14, 2014 Adults who are planning ... Quotes Pros website to find quotes for life insurance ... year at http://quotespros.com/life-insurance.html is now delivering the ... partners that are preparing the rates information for adults ... most U.S. states. As a way to simplify the ...
(Date:9/14/2014)... September 14, 2014 Proper oral care ... from Butte, Mont., found a way to teach children ... patent-pending B LITE toothbrush encourages an effective brushing habit ... full two minutes without overbrushing, eliminating guesswork and promoting ... easy to use, suitable for all children, and producible ...
(Date:9/14/2014)... SUNDAY, Sept. 14, 2014 (HealthDay News) -- Getting enough sleep each ... work due to illness, a new study suggests. The study ... who were followed for an average of seven years. Those ... a night were much more likely to have extended absences from ... risk for taking time off from work due to sickness were ...
Breaking Medicine News(10 mins):Health News:How to Start And Run a Successful Legal Marijuana Business 2Health News:iConcox GPS Vehicle Tracker GT06N Designed for Customers' Security 2Health News:Quotes for Life Insurance Now Offered at New Consumer Portal Online 2Health News:A Good Night's Sleep May Mean a Good Day's Work 2
... Kozhikode have claimed that homeopathy offers a cure for ... several medicines like Uppttorium, Rextokes and Brayonia could effectively ... in the hospital that the Andhra Pradesh Government ... Tamil Nadu and Karnataka were also contemplating similar measures, ...
... is an integral part of health, and assessment of sleep ... to an editorial in the September 18 issue of Archives ... The issue is devoted to studies of sleep and health. ... that sleep serves as an indicator of health and quality ...
... of Similac Infant Formula were off the shelf, after its ... a suspected flaw in the bottle. No repercussions after the ... company has decided to recall the product in order to ... content in the bottle. ,Given below ...
... will soon ban gifts like coffee mugs, notepads, pens ... the Stanford University Medical Center offices.// ,The rules, expected ... physicians and medical students at Stanford University to accept ... representative selling drugs, medical devices or related products. ...
... from the rich countries to achieve the universal goal of ... ,Five times more money is needed to meet the goal ... papers published online by the Lancet today. It coincides with ... Norwegian government. , ,According to Timothy Powell-Jackson and ...
... than 1.6 million U.S. adults are estimated to use ... sleeping, according to the results of a// national survey ... Internal Medicine, a theme issue on sleep. ... difficulty sleeping, also known as insomnia, according to background ...
Cached Medicine News:Health News:Incorporate Sleep Evaluation into Routine Medical Care 2Health News:Pharmaceutical Companies Banned from Giving Gifts at Stanford 2Health News:Pharmaceutical Companies Banned from Giving Gifts at Stanford 3Health News:Pharmaceutical Companies Banned from Giving Gifts at Stanford 4Health News:Child death reduction needs five times more funds 2Health News:About 5 Percent of Adults with Insomnia Use Alternative Therapies 2
... PoliPhase® is a biologically based ... two component system consisting of a ... the control of internal bleeding. ... readily flow on to a prepared ...
The DuraSeal System includes an innovative polyethylene glycol hydrogel sealant and applicator packaged in a single-use kit which can be stored at room temperature for convenience and quick preparati...
... DERMABOND* Topical Skin Adhesive gives you ... adhesive is intended for topical application only ... of wounds from surgical incisions, including punctures ... cleansed, trauma-induced lacerations. DERMABOND adhesive may be ...
... BD Cell-Tak™ Cell and Tissue Adhesive is ... Mytilus edulis (marine mussel). These proteins are ... by the mussel to anchor itself to ... Cell-Tak Cell and Tissue Adhesive is used ...
Medicine Products: